BBX Logo Beta

LIXTE Biotechnology Holdings, Inc. (LIXT)

Crypto Stocks
LIXTE Biotechnology Holdings, Inc.
Tue, 5/26/2026, 06:06:03 AM
logo
LIXTE Biotechnology Holdings, Inc.
$LIXT
Non-Strategic Token Holding
$5.85
--
Company Information

LIXTE Biotechnology is a clinical-stage biopharmaceutical company focused on discovering and developing novel drugs for the treatment of cancer. Their main research direction is protein phosphatase 2A (PP2A) inhibitors, which they believe have therapeutic potential in various cancers, especially when used in combination with cytotoxic drugs, radiotherapy, immune checkpoint inhibitors, and others.

Coin Reserve Status
BTC
币种储备情况
Main Held Cryptocurrencies: No data available
Amount Held: No data available
Current Value: No data available
Proportion of Total Assets: No data available
Reserve Management Strategy: No data available
Long press to scan QR code for more content
LIXTE Biotechnology Holdings, Inc.

LIXTE Biotechnology Holdings, Inc.

$LIXT
Non-Strategic Token Holding
Buy Token

Company Information

LIXTE Biotechnology is a clinical-stage biopharmaceutical company focused on discovering and developing novel drugs for the treatment of cancer. Their main research direction is protein phosphatase 2A (PP2A) inhibitors, which they believe have therapeutic potential in various cancers, especially when used in combination with cytotoxic drugs, radiotherapy, immune checkpoint inhibitors, and others.
CEO
Mr. Geordan G. Pursglove
Founded
2005
Headquarters
680 East Colorado Boulevard, Suite 180, Pasadena, CA 91101, United States
EXCHANGE
N/A
H
Annual High
$6.09
L
Annual Low
$2.39

Stock Chart

Business Model

Business Mode

  • Business Model: LIXTE Biotechnology Holdings, Inc.'s business model is that of a clinical-stage biopharmaceutical company focused on identifying drug development targets for cancer and developing and commercializing cancer therapies. Its core lies in identifying cancer drug targets, developing innovative therapies, and validating their efficacy and safety through clinical trials.

Profit Model

  • Profit Model: The profit model of LIXTE Biotechnology Holdings, Inc. primarily comes from the sales revenue of its cancer drugs after obtaining approval. During the research and development phase, its profitability relies on external investments, partnership agreements, and milestone payments. Its profit prospects are closely related to the success of clinical trials, the market potential of the drugs, and commercialization capabilities.

Profit Model Impact

  • LIXTE Biotechnology Holdings, Inc.'s business and profit model mainly focus on the biopharmaceutical field, and there is currently no clear information indicating that its profit model has a direct connection to cryptocurrency. Therefore, its profit model does not have a direct impact on the cryptocurrency market.

Impact on Cryptocurrencies

  • Directly Affected Coins: No data available
  • Indirectly Affected Coins: No data available